Pfizer De-Risks Renal Drug Development Via SFJ Pharma Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
In another sign of Big Pharma’s growing need to curb development cost and risk, Pfizer has engaged drug development company SFJ Pharmaceuticals to fund and supervise a Phase III trial of renal cancer candidate axitinib in Asia.